Genetak adopts new technology for genomic medical treatments
Now, the Kuwaiti company plans to make the platform available directly to other clinical laboratories and hospitals throughout the Middle East.
Dr. Fahd Al-Mulla, director of the Genatak-Global Medical Clinic, said exome and whole genome sequence data have always been considered considerable bottlenecks for a diagnostic or research laboratory. He said getting information from genomes is an easy enough task, but going through the data requires massive amounts of work from specialists the Middle East has far too few of.
“The scarcity of bioinformatic experts, especially in the Middle East, as well as the rapidly changing nature of the required analysis, the lack of properly curated variation databases and the anxiety of clinicians in handling big data are major obstacles hindering the successful implementation of genomic medicine in clinical practice,” Al-Mulla said.
That’s why Genatak is heavily investing in state-of-the-art technology and highly trained clinicians who are able to offer their patients the most current evidence-based medicine and therapeutics.
That investment is what led Genetak to adopt the Tute Genomics Platform. The platform works to empower molecular laboratories, clinicians, and other frontline health care providers to rapidly process, interpret and generate clinical reports on large volumes of genomic sequence data.
"Bioinformatics challenges are magnified several fold when it comes to implementing genomic medicine in the Middle East, because Arab-Middle East specific variants are nowhere to be found in major databases,” Al-Mulla said. “Compared to other pipelines we designed in-house or have previously tested, the Tute Genomics pipeline is truly a trustworthy, credible and accessible platform."